A6533886 Bond Yield and Price — FINRA:A6533886
This article provides detailed information about the AGILENT TECHNOLOGIES INC 4.9% 15-JAN-2032 bond, identified by FINRA:A6533886. It includes key terms such as outstanding amount, face value, coupon rate, and maturity date, along with issuer information like company sector and industry. The article also describes Agilent Technologies, Inc.'s business segments: Life Sciences and Diagnostics Markets, Applied Markets, and Agilent CrossLab.
Agilent Technologies stock trades at USD 167.83 after Q3 beat
Agilent Technologies (A) stock closed at USD 167.83 on October 2, 2026, after reporting a Q3 adjusted EPS of USD 1.62, beating estimates by USD 0.13, and an 8.1% year-over-year revenue increase to USD 1.88 billion. Analysts maintain a "Moderate Buy" consensus with an average price target of USD 170.33, indicating a modest upside. The company also declared a quarterly dividend of USD 0.255 per share, payable on October 28, 2026.
Agilent Technologies stock reflects raised 2026 guidance
Agilent Technologies stock is priced at USD 167.77 after reporting strong fiscal Q3 results, with revenue reaching USD 1.88 billion and adjusted EPS at USD 1.62, beating consensus estimates. The company has raised its fiscal 2026 revenue guidance to USD 7.49 billion to USD 7.51 billion and adjusted EPS guidance to USD 6.18 to USD 6.21, reflecting robust performance in pharma and advanced therapeutics. Agilent also declared a quarterly dividend of USD 0.255 per share, payable on October 28, 2026.
Agilent launches TapeStationDx as Agilent Technologies stock costs EUR 149.10 versus EUR 149.10
Agilent Technologies launched three TapeStationDx products for regulated clinical next-generation sequencing workflows on September 21, 2026. The company's stock traded at EUR 149.10 in weekend trading on October 3, 2026, unchanged from the previous close. Agilent also announced a quarterly dividend of 25.5 cents per share, payable on October 28, 2026.
Agilent Technologies Inc (A) Shares Fall 3.3% -- GF Value Says Still Overvalued
Agilent Technologies Inc (A) shares dropped 3.3% to $166.68, and GuruFocus's GF Value indicates the stock is 11.3% overvalued with a GF Value of $149.70. Despite a strong GF Score of 95/100 and high profitability, the valuation and insider selling activity suggest caution for potential investors. Insiders have sold $3.2 million worth of shares in the past year with no buying activity.
Agilent Introduces NovoStation Sample Prep System to Automate Flow Cytometry Workflows
Agilent Technologies has launched its NovoStation Sample Preparation System, designed to automate flow cytometry sample preparation and integrate with its NovoCyte flow cytometer and NovoExpress software. This new system significantly reduces hands-on time for scientists, cutting it by over 90% in validation studies while maintaining data quality. The automation allows researchers to focus more on scientific innovation and interpretation of results, addressing the increasing demand for higher-throughput workflows in various research settings.
$1000 Invested In Agilent Technologies 15 Years Ago Would Be Worth This Much Today
Agilent Technologies (NYSE: A) has significantly outperformed the market over the last 15 years, achieving an average annual return of 14.43%. An initial investment of $1000 in Agilent stock 15 years ago would now be valued at $7,065.54. This demonstrates the substantial impact of compounded returns on investment growth over time.
A 30-sample lab process took 7.9 minutes of hands-on time with Agilent's system, versus 85.5 minutes manually.
Agilent Technologies Inc. launched the NovoStation Sample Preparation System, an automated platform designed to simplify and streamline flow cytometry sample preparation. This system significantly reduces hands-on time for laboratory technicians, with validation studies showing a more than 90% reduction compared to manual processes. The NovoStation aims to improve efficiency, consistency, and data quality in high-throughput flow cytometry workflows across various research settings.
Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows
Agilent Technologies Inc. has launched the NovoStation Sample Preparation System, an automated platform designed to simplify and streamline sample preparation for flow cytometry. This system, when paired with NovoCyte flow cytometers and NovoExpress software, creates a hands-free, sample-to-answer workflow, significantly reducing manual labor and variability. Validation studies show it can cut hands-on time by over 90% while maintaining data quality, enhancing efficiency and reproducibility in laboratories.
Bullish on Agilent Technologies Inc
Agilent Technologies (A-N) experienced a significant rise from March 2020 to August 2021 but reversed course in 2022, settling into a horizontal trading range. The stock's recent breakout above this range signals a new up-leg, with initial targets of US$180 and US$195. Solid support for the stock is near US$145–150.
Agilent Technologies Inc. stock outperforms competitors on strong trading day
Agilent Technologies Inc. (A) stock rose 1.40% to $175.21 on a challenging day for the broader market, with the S&P 500 and Dow Jones Industrial Average both declining. The company's stock also reached a new 52-week high, surpassing its previous peak of $174.77.
Agilent Ekes on Launch of BioTek
Agilent Technologies Inc. (NYSE: A) has announced the launch of its BioTek Gen5 AI cell identification module, an image analysis software add-on incorporating AI-based cell identification. This module aims to simplify cell counting and confluence analysis by removing the need for conventional threshold setting, thereby reducing user-dependent variation in laboratory workflows. Following the announcement, Agilent shares saw a gain of $1.54, reaching $176.74.
Agilent Ekes on Launch of BioTek
Agilent Technologies Inc. announced the launch of the Agilent BioTek Gen5 AI cell identification module, an image analysis software add-on that incorporates AI-based cell identification and segmentation into BioTek Gen5 imaging analysis. This module, designed for use with compatible Agilent BioTek automated imaging systems, aims to simplify image analysis and improve consistency by using AI segmentation without conventional threshold setting. Agilent shares gained $1.54 to $176.74 following the announcement.
Agilent launches AI cell identification software module
Agilent Technologies Inc. has launched its new BioTek Gen5 AI cell identification module, an image analysis software add-on that uses AI-based segmentation for cell identification. This module aims to streamline image analysis by eliminating the need for conventional threshold settings and parameter tuning, thereby reducing manual effort and user-dependent variations. It supports various life science and pharmaceutical research applications, making AI-based cell analysis more accessible.
Agilent launches AI cell identification software module By Investing.com
Agilent Technologies Inc. has launched the BioTek Gen5 AI cell identification module, an image analysis software add-on that integrates AI-based cell identification and segmentation into its BioTek Gen5 imaging analysis. This new module is designed to simplify cell counting and confluence analysis by reducing the need for manual image-analysis steps and conventional threshold setting. The software aims to make AI-based cell analysis more accessible for various life science research applications, including drug discovery.
New AI software identifies cells without researchers tuning analysis settings
Agilent Technologies Inc. has launched the BioTek Gen5 AI cell identification module, a new image analysis software add-on that brings AI-based cell identification and segmentation to BioTek Gen5 imaging workflows. This module aims to simplify the analysis process for researchers by eliminating the need for conventional threshold setting or parameter tuning, thereby reducing manual steps and supporting consistent cell counting and confluence analysis. The software supports various assays, including label-free, fluorescence, live-cell, and kinetic assays, making AI-based cell analysis more accessible for life science and pharmaceutical research.
Form 8K Agilent Technologies For: 28 September By Investing.com
This article reports on an 8K filing by Agilent Technologies for September 28. The content is very brief, providing only the title and publication details, and is surrounded by numerous financial market data, news headlines, and navigational elements from the Investing.com platform. It indicates that Agilent Technologies made a Form 8K disclosure on the specified date.
Form 8K Agilent Technologies For: 28 September
This article reports on the filing of a Form 8K by Agilent Technologies for September 28, 2026. The brief report, published by Investing.com, provides no further details about the content of the Form 8K.
BofA Securities Maintains Agilent Technologies(A.US) With Buy Rating, Maintains Target Price $180
BofA Securities has reiterated its Buy rating on Agilent Technologies (A.US) and maintained its price target at $180. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Agilent Technologies stock follows a Q3 beat as targets diverge
Agilent Technologies (A) reported a strong Q3 performance with adjusted EPS of $1.62 and revenue of $1.88 billion, exceeding analyst consensus. Management raised its fiscal 2026 adjusted EPS guidance, reflecting robust operational details including strong cash flow and growth in pharma and China. Despite a positive earnings beat, analyst price targets for Agilent remain split, with UBS cutting its rating to Neutral while Baird raised its target, indicating divergent views on the stock's future trajectory.
Agilent Technologies Inc (A): GF Score of 96 Signals Strong Outp
Agilent Technologies Inc (A) has a GF Score of 96, indicating strong outperformance potential due to its robust financial health, high profitability, and consistent growth. The company, a life sciences and diagnostics provider, demonstrates strong financial strength with a 7/10 rank, perfect 10/10 profitability and momentum ranks, and a 9/10 growth rank. While its GF Value rank is 6/10, suggesting it's not deeply undervalued, its overall financial stability and operational efficiency make it a compelling investment for long-term growth.
Agilent Technologies stock trades at USD 172.68 near its 52-week high
Agilent Technologies stock is trading at $172.68, close to its 52-week high, following strong Q3 FY2026 results which showed an 8.1% revenue increase year-over-year to $1.88 billion and improved GAAP and non-GAAP EPS. The company also raised its fiscal 2026 revenue and non-GAAP EPS guidance. Barclays raised its price target for Agilent from $150 to $175, maintaining an Overweight rating.
New Products: Qiagen, Helix, Countable Labs, AtlasBio, Revvity, Agilent
This article lists new product releases from several companies in the biotechnology and life sciences sectors. The companies mentioned include Qiagen, Helix, Countable Labs, AtlasBio, Revvity, and Agilent. The brief entry indicates a focus on new technologies and offerings in the market.
Agilent Technologies stock gains 3.9 percent ahead of the open
Agilent Technologies stock rose 3.9 percent to USD 171.72 on September 24, 2026, outperforming the Nasdaq Composite. The company's recent fiscal third-quarter earnings report and the launch of TapeStationDx systems are cited as drivers for investor interest. Analysts have also reportedly raised price targets for the stock.
Why Agilent Technologies (A) Stock Is Up Today
This article explains why Agilent Technologies (A) stock experienced an increase today.
Strength Seen in Kestra Medical Technologies, Ltd. (KMTS): Can Its 8.1% Jump Turn into More Strength?
Kestra Medical Technologies, Ltd. (KMTS) saw an 8.1% share price increase after regulatory filings clarified that recent executive stock sales were non-discretionary tax-related transactions, not insider selling. Despite a positive market reaction, the company's consensus EPS estimate for the upcoming quarter has been revised lower, and it currently holds a Zacks Rank #3 (Hold), suggesting caution for continued strength.
Agilent Technologies stock hits 52-week high at 169.07 USD
Agilent Technologies (NYSE: A) stock recently hit a 52-week high of $169.07, demonstrating significant investor confidence and strong market performance with a 37.56% increase over the past year and a 45.37% return in six months. This surge is supported by 11 analysts revising earnings upwards and stronger-than-expected fiscal third-quarter results, prompting raised price targets from multiple firms. Despite these positive indicators, InvestingPro data suggests the stock might be overvalued relative to its Fair Value estimate.
Agilent Technologies stock hits 52-week high at 169.07 USD By Investing.com
Agilent Technologies stock reached a new 52-week high of $169.07, demonstrating significant growth with a 37.56% increase over the past year and 45.37% over six months. This surge is supported by strong fiscal third-quarter results, surpassing Wall Street forecasts, and multiple analyst price target increases. Despite the strong performance, InvestingPro data suggests the stock might be overvalued relative to its Fair Value.
AGILENT TECHNOLOGIES, INC. SEC Filing (Sep 24, 2026)
Agilent Technologies, Inc. filed an S-4 form with the SEC, which became effective on September 23, 2026, at 4:00 P.M. The filing was accepted by SEC EDGAR on September 24, 2026, at 12:15 AM. Agilent (NYSE: A) is ranked by market cap, dividends, and as a gainer in various timeframes, with a market capitalization of $46.61 billion.
Agilent Technologies stock reports 8.1 percent revenue growth
Agilent Technologies reported a Q3 revenue of USD 1.878 billion, an 8.1% increase year-over-year, and exceeded analyst expectations for both revenue and adjusted EPS. The company also raised its fiscal 2026 revenue guidance to between USD 7.49 billion and USD 7.51 billion. Despite the strong performance, Agilent's stock was trading slightly below its 52-week high at USD 165.32.
If You Invested $1000 in Agilent Technologies a Decade Ago, This is How Much It'd Be Worth Now
This article examines the investment performance of Agilent Technologies (A) over the past decade. A $1000 investment in Agilent Technologies ten years ago would now be worth $3,583.89, representing a 258.39% gain, outperforming both the S&P 500 and gold over the same period. Analysts are optimistic about Agilent's future, citing sustained instrument demand, pharma exposure, and recent product launches.
Agilent Technologies Sees Growth From China, Replacement Cycles and Lab Automation
Agilent Technologies executives discussed growth drivers including improving end markets, market-share gains, instrument replacement cycles, and the Ignite transformation program. The company sees continued strength from China, with investments in pharmaceuticals and advanced materials, and significant opportunities in both liquid and gas chromatography replacement cycles. Additionally, Agilent is focusing on lab automation and scientific intelligence, with AI as a key enabler, and expanding its advanced therapeutics CDMO business.
Agilent Technologies Analysis: 3.29% Surge Highlights Strong Momentum
Agilent Technologies (NYSE: A) experienced a 3.29% surge, closing at $167.26, indicating a strong bullish trend. However, technical indicators like RSI show the stock is significantly overbought on daily and hourly charts, suggesting a potential near-term pause or pullback. Key levels to watch include the daily pivot at $165.29 and resistance at $169.55 to determine if the rally will continue or if a correction is imminent.
Why Did Agilent Technologies (A) Shares Climb After Its Latest Update?
Agilent Technologies (A) recently saw its shares climb after expanding its clinical lab footprint with new CE-IVD-labeled TapeStationDx instruments and software for DNA and RNA quality control in regulated next-generation sequencing workflows. The company has experienced significant share price returns, indicating building momentum. Despite being considered 4% undervalued by a fair value narrative, the article notes potential risks from elevated tariff costs or tightened research funding.
Grand Canyon Education shares drop 28% on AI fears despite strong enrollment and finances
Grand Canyon Education (LOPE) shares have dropped 28% over the past year due to AI disruption concerns, despite the company reporting strong Q2 2026 results with broad enrollment growth, particularly in its profitable hybrid segment. The company maintains a debt-free balance sheet, strong cash flow, and continues share buybacks. Its current valuation is 38% below recent peaks, potentially offering a buying opportunity.
Agilent Technologies Inc. stock outperforms competitors on strong trading day
Shares of Agilent Technologies Inc. rose by 3.29% to $167.26 on Tuesday, marking its sixth consecutive day of gains. This strong performance occurred during a mixed trading session for the broader stock market, where the S&P 500 Index remained mostly unchanged and the Dow Jones Industrial Average saw a slight decline.
Agilent Technologies price pierces price target - Forecast today - 22-09-2026
Agilent Technologies, Inc. (A) has broken above its previous price target of $158.00 with increased trading volume, maintaining a bullish outlook. The stock is supported by its 50-day Simple Moving Average and an ascending trendline, with momentum indicators also signaling continued upward movement. The next target resistance level is projected at $169.50, provided the stock stays above $158.00.
Cue Biopharma rated Buy after positive phase 2 results show superior efficacy in treating chronic spontaneous urticaria.
Cue Biopharma has received a Buy rating following promising Phase 2 trial results for its drug CUE-221, which demonstrated superior efficacy in treating chronic spontaneous urticaria (CSU) compared to XOLAIR. The drug achieved complete hive resolution in 54% of patients at 12 weeks. While upcoming milestones include further pharmacokinetic and IgE data in 2026 and planned Phase 2b/3 studies, the company faces a financial challenge with only a 12-month cash runway despite recent financing.
Goldman Sachs Adjusts PT on Agilent Technologies to $185 From $175, Maintains Buy Rating
Goldman Sachs has increased its price target for Agilent Technologies (NYSE: A) to $185 from $175, while reiterating a Buy rating on the stock. This adjustment reflects the analyst's updated valuation for the company.
Agilent Launches TapeStationDx Systems for Clinical NGS Sample Quality Control
Agilent Technologies has launched its new Agilent TapeStationDx systems and software, extending its automated electrophoresis portfolio into regulated clinical laboratory environments. These CE-IVD-labeled systems are designed to standardize and ensure traceable quality control of DNA and RNA samples used in clinical next-generation sequencing (NGS) workflows, addressing increasing regulatory expectations and the need for efficient sample assessment in clinical laboratories. The systems offer fast, automated sample quality control and data integrity features to support compliance with regulations like 21 CFR Part 11 and EU Annex 11.
Agilent launches clinical lab systems for DNA, RNA analysis By Investing.com
Agilent Technologies Inc. has introduced two new TapeStationDx systems and accompanying software for DNA and RNA quality control in clinical laboratories. These CE-IVD labeled systems, the 4150 TapeStationDx and 4200 TapeStationDx, are designed to integrate into clinical next-generation sequencing workflows, offering automated electrophoresis and compliance features. They are available in the US, Canada, and several European markets, with Agilent planning to showcase them at upcoming scientific conferences.
Goldman Sachs Adjusts PT on Agilent Technologies to $185 From $175, Maintains Buy Rating
Goldman Sachs has increased its price target for Agilent Technologies (NYSE: A) to $185 from $175, while reaffirming a Buy rating on the stock. This adjustment comes amidst other analyst actions, including a recent downgrade by UBS and an upgrade by Baird, reflecting varying perspectives on Agilent's future performance. The company recently announced a quarterly dividend of $0.255 per share, payable on October 6, 2026.
Agilent (A) Wants Pathology Labs To Go Digital, 540 Slides At A Time
Agilent Technologies (A) has launched a new slide scanner, the Agilent S540MD, in the U.S., capable of holding 540 glass slides. This FDA-cleared device aims to help pathology labs digitize their workflows and prepare for AI assistance, leveraging Agilent's expertise despite the underlying hardware being from Hamamatsu. The launch follows a strong financial quarter for Agilent, though the full impact of the scanner on revenue remains to be seen.
Agilent Technologies Inc. 2017 Q3 - Results - Earnings Call Slides (NYSE:A)
This article provides access to the earnings call slides published by Agilent Technologies Inc. for their 2017 Q3 results. The company reported an EPS of $0.59, beating estimates by $0.07, and revenue of $1.11 billion, which was up 6.70% year-over-year and beat estimates by $27.22 million. The slides accompany the earnings call from August 15, 2017.
Agilent Announces Cash Dividend of 25.5 Cents per Share
Agilent Technologies Inc. announced a quarterly cash dividend of 25.5 cents per share of common stock. This updated release corrects an earlier version regarding the payment and record dates for the dividend. The dividend will be paid on October 28, 2026, to shareholders of record as of October 6, 2026.
CORRECTING and REPLACING Agilent Announces Cash Dividend of 25.5 Cents per Share
Agilent Technologies Inc. (NYSE: A) has issued a corrected announcement regarding its quarterly cash dividend of 25.5 cents per share. The updated information states that the dividend will be paid on October 28, 2026, to shareholders of record as of October 6, 2026, correcting the previously misstated dates.
Agilent declares quarterly dividend of 25.5 cents per share
Agilent Technologies Inc. announced a quarterly dividend of 25.5 cents per share of common stock. The dividend is scheduled to be paid on October 6, 2026, to shareholders of record as of October 28, 2026. The company, which generated $6.95 billion in revenue in fiscal year 2025, stated that future dividend timing and amounts are subject to board approval.
Agilent declares quarterly dividend of 25.5 cents per share By Investing.com
Agilent Technologies Inc. announced a quarterly dividend of 25.5 cents per share of common stock. The dividend is scheduled to be paid on October 6, 2026, to shareholders of record as of October 28, 2026. Agilent, an analytical and clinical laboratory technologies company, generated $6.95 billion in fiscal year 2025 revenue.
Q2 Rundown: Revvity (NYSE:RVTY) Vs Other Research Tools & Consumables Stocks
The article reviews the Q2 performance of Revvity (NYSE:RVTY) and other companies in the research tools & consumables industry. It highlights Revvity's strong quarter with revenues of $711.1 million, while also detailing the best performer, Avantor (NYSE:AVTR), and the weakest, Bruker (NASDAQ:BRKR), among its peers. The sector as a whole reported strong Q2 results, with revenues beating consensus estimates by 1.7%.
Agilent to Participate in J.P. Morgan U.S. All Stars Conference
Agilent Technologies Inc. announced that its CEO, Padraig McDonnell, and CFO, Adam Elinoff, will participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference. The event is scheduled for September 23, 2026, in London, and a live audio webcast will be available on Agilent's Investor Relations website. Agilent is a global leader in analytical and clinical laboratory technologies, with revenues of $6.95 billion in fiscal year 2025.
